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SequencingAbstract Duchenne muscular dystrophy (DMD) is the most common form of muscular dystro-
phies affecting approximately 1:3500 male live births. Deletion of the dystrophin gene accounts
for approximately 65% of mutations, duplications occur in 6–10% while the remaining 20–30%
are point mutations, small deletion/insertions, or splicing mutations.
Aim: To study non-deletion mutations in a sample of Egyptian patients with DMD as most pre-
vious studies focused on deletion mutations.
Patients and methods: The study included 25 patients with DMD from 18 different families from
the genetics clinic, Children’s Hospital, Ain Shams University. Diagnosis was made based on typical
clinical ﬁndings, high CPK and EMG result. Molecular analysis included Polymerase Chain Reac-
tion (PCR) followed by multiplex ligation-dependent probe ampliﬁcation (MLPA) to those patients
with no deletion by PCR. Direct sequencing of the whole dystrophin gene was done to those
patients who had no deletion or duplication by the previous 2 methods.
Results: Non-deletion mutation included duplications (5 families (27.8%)) which are higher than
previously reported and point mutation (c.583C>T) in only one family. Deletion mutations were
found in 9 families (50%) and no mutation found in 3 families (16.7%). Interestingly, 60% of
the duplications were located in the distal region of the dystrophin gene. A frame shift mutation
236 R.M. Shawky et al.was identiﬁed in most patients (93%) except one with duplication of exons 50–51 who had an unex-
pected severe disease with an early age of onset. Also, an intragenic deletion involving the 50 end of
the dystrophin gene (deletion of muscle protomor and exon 1) was found in another patient with
severe disease without cardiac involvement.
Conclusion: The relative higher frequency of duplication mutations in Egyptian patients with
DMD may indicate that MLPA and not PCR should be preferred for molecular testing of Egyptian
patients with DMD.
 2014 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.1. Introduction
Duchenne muscular dystrophy (DMD; MIM# 310200) is the
most common form of all muscular dystrophies caused by
mutations within the dystrophin gene and is inherited as X-
linked recessive. It is a serious condition with progressive mus-
cle wasting and weakness with most affected boys becoming
wheelchair-bound by the age of 12 years and dead by their
20s. A similar but milder condition (known as Becker muscular
dystrophy (BMD; MIM# 300376) is caused by mutation in the
same gene. The incidence of DMD is approximately 1:3500
male live births [1].
The DMD gene is structurally complex, with 79 exons and
7 promoters, comprising 2.4 million base pairs, making it one
of the largest genes known to date [2]. Previous reports sug-
gested that large deletions account for approximately 65% of
DMD mutations and 85% of BMD mutations. Duplications
occur in roughly 6–10% of males with either DMD or
BMD. The remaining 20–30% of mutations are point muta-
tions, small deletion/insertions, or splicing mutations [3]. Most
of point mutations lead to premature translational termination
due to nonsense (34%), frameshift (33%), splice site (29%),
and missense (4%) mutations in the dystrophin gene [4].
Unlike the large deletions that cluster in just two regions, point
mutations are more randomly distributed throughout the dys-
trophin gene [3]. To date, 2556 unique point mutations have
been documented in the dystrophin gene [5].
The identiﬁcations of the causing mutation in the dystro-
phin gene is considered very important because it may provide
new insights into the function of dystrophin and direct infor-
mation for genetic counseling, prenatal diagnosis and carrier
studies [3,6]. Furthermore accurate molecular diagnosis is
essential for different recent mutation speciﬁc therapeutic
modalities [7].
The aim of this work was to study the non-deletion muta-
tion spectrum in Egyptian patients with DMD because all pre-
vious studies focused on deletions only [8–11] and to ﬁnd the
most appropriate molecular method for accurately diagnosing
the largest number of our patients.
2. Patients and methods
The study included 25 patients with DMD from 18 different
families from the genetics clinic, Children’s Hospital, Ain
Shams University. Diagnosis was made based on typical clini-
cal ﬁndings (progressive symmetric muscular weakness starting
65 years (proximal greater than distal) often with calf hyper-
trophy), high CPK (>10· normal) and EMG showing myo-
pathic pattern.Molecular analysis included
1. Detection of deletion mutations by using Polymerase Chain
Reaction (PCR) and amplifying the 79 exons and the
Dp427m promoter of the dystrophin gene [12,13].
2. Multiplex ligation-dependent probe ampliﬁcation (MLPA)
was done to those patients with no deletion by PCR using
commercial MLPA kits (MRC-Holland, Amsterdam, The
Netherlands) according to the manufacturer’s instructions
(http://www.mrc-holland.com) [14].
3. Sequencing of the whole dystrophin gene was performed in
those patients who had no deletion or duplication by the 2
previous methods using ABI 3037 [15].
The study was approved by the ethics committee of the
institute and informed consent was obtained from the parents.
The study was carried out in accordance to the code of Ethics
of the World Medical Association (Declaration of Helsinki)
for experiments involving humans.
3. Results
3.1. Clinical ﬁndings
Patients’ ages ranged between 4 and 20 years. The mean age at
diagnosis was 4.5 ± 1.8 years (range 2–9 years). The age of
onset was before 5 years in 16 (64%) patients and at the age
of 5–10 years in 9 (36%). The main presenting symptoms at
the time of diagnosis was abnormal gait in 9 cases (36%), fre-
quent falls in 7 cases (28%), difﬁculty in climbing up stairs in 6
cases (24%), standing up difﬁculties in 2 cases (8%) and
delayed motor milestones in one case (4%). The mean age of
walking was 18 months (range 12–30 months). Six patients
(24%) were wheelchair-bound at the time of the study; they
lost independent ambulation at a mean age of 10 years (range
9–12 years). Mild to moderate mental retardation was detected
in 10 DMD cases (40%). Family history revealed a similar
affected member in 9 families (3 sibs and 6 maternal cousins).
3.2. Laboratory investigations
a. Serum CPK levels ranged between 2134 IU/L and
24,000 IU/L with a mean of 11,273 ± 5426 IU/L (nor-
mal: 38–173 IU/L).
b. Echocardiography revealed cardiomyopathy in four
patients (16%), all of them were above the age of
10 years.
c. Mutation analysis, Table 1:
Table 1 Distribution of mutation found in the studied 18 DMD patients multiplex.
Family
no.










No mutation found by PCR/
MLPA/sequencing
1 – – – + – –
2 – E 50–51 –  MLPA In frame
3 – – c.583C>T  Sequencing
–
4 – E 16–17 –  MLPA Out of frame
5 – E 45–52 –  MLPA Out of frame
6 E 49–50 –  PCR Out of frame
7 – E 50–52 –  MLPA Out of frame
8 E 45 –  PCR Out of frame
9 E 45 –  PCR Out of frame
10 E 49–62 –  MLPA Out of frame
11 E 1 & prom
(DP427 m)
– –  PCR Out of frame
12 E 45 – –  PCR Out of frame
13 E 49–54 – –  PCR Out of frame
14 – – – + – –
15 – – – + – –
16 E 52 – –  PCR Out of frame
17 E 46–55 – –  PCR Out of frame
18 E 45 – –  PCR Out of frame
Total 9 (50%) 5 (27.8%) 1 (5.5%) 3 (16.7%) – –
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revealed deletions within the dystrophin gene in 9 families
(50%). This included single exon deletion in 5 families
(55%) and multiple exon deletions in 4 (45%). Exon 45
was the most common deleted exon accounting for 44.4%
of all deletions. 89% of the deletions were located in the dis-
tal hot spot region (exons 45–55) of the dystrophin gene;
only one patient (11%) had deletion in the 50 end region.
– MLPA analysis identiﬁed duplicationmutations in 5 families
(27.8%), which were all multi-exon duplications, Table 1.
– Sequencing of the dystrophin gene revealed a single nucleo-
tide substitution (c.583C>T) which predicted to create a
stop codon in exon 7 (p.Arg195X) in only one family
(Fig. 1). No mutation was found in 3 families (16.7%).
– Reading frame rule and genotype–phenotype correlations.
The reading frame rule using frame shift checker of Leiden
Muscular Dystrophy website (www.dmd.nl/) was applied to
the 14 patients with deletions or duplications. A frame shift
was detected in 13 (93%) patients while an in-frame mutation
was found in only one patient presenting with a duplication of
exons 50–51 (patient no. 2, Table 1). The latter variant is
exceptional in respect of the frame shift hypothesis because
he had a relatively severe disease with an early age of onset.
An intragenic deletions involving the 50 end of the dystrophin
gene (deletion of muscle protomor and exon 1) in patient no.
11 was observed to be associated with earlier onset of disease
(2 years) and more severe symptoms (wheel-chaired at age of
9 years) but without any cardiac involvement at the time of
examination. Although four of the patients carried the same
mutation (exon 45 deletion), they had variable ages of onset
and variable disease course. In the remaining mutations iden-
tiﬁed, no clear phenotype–genotype correlation could be
found.4. Discussion
This is the ﬁrst Egyptian study applying sequencing of dystro-
phin gene searching for non-deletion mutations in DMD
patients. Interestingly, it revealed a higher frequency of dupli-
cation mutations (27.8%) than previously reported (10.3%)
[16]. Although this high frequency can be attributed to the
small number of patients, a true high frequency of duplication
mutations among Egyptian DMD patients cannot be excluded.
It also indicates that the MLPA and not PCR should be the
best method to start with for a molecular diagnosis of Egyp-
tian DMD patients.
Similar high frequencies of duplication mutation were pre-
viously reported in the Bulgarian population (27%) and Tai-
wanese population (24.7%) [17,18].
A previous Egyptian study revealed duplication in only 2
out of 41 patients (5%) [11]. This low percentage can be
explained by the lower number of exons studied (only 18 exons
were analyzed).
Another interesting ﬁnding is that 60% of duplications
found in this study were located in the distal region of dystro-
phin gene. This is in contrast to what was reported in other
populations where a higher percentage of duplications is
located in the proximal region [19,20].
Regarding deletion mutations, the frequency found is
almost similar to previous studies (Table 2). Higher frequen-
cies were reported only by Bastaki et al. and El sheriff et al.
(75% and 61%, respectively) [11,21]. This high incidence is
probably due to the fact that both studies were performed
on only immunohistochemistry conﬁrmed DMD patients, a
technique that we did not include in this analysis due to its
local unavailability.
The frequency of deletion mutations also lies between high-
est deletion frequencies of Kuwait, Canada and Greece (86%,
Figure 1 Sequencing of patient No. 3 showing a nonsense point mutation (c.583C>T) in exon 7.
Table 2 Percentages of deletions and duplication found in different Egyptian studies.
Study No. of Samples No. of exon tested Method used Deletion% Duplication%
Baskati et al., [21] 26 25 mPCR 75 –
Eﬀat et al., [8] 100 18 mPCR 55 –
Elhawary et al., [9] 152 10 mPCR 51.3 –
Shawky et al., [10] 59 9 mPCR 55.9 –
El Sherif et al., [11] 41 25 qPCR 61 5
Present study 25 All 79 PCR, MLPA 50 27.8
mPCR: multiples PCR, qPCR: quantitative PCR, MLPA: multiplex ligation-dependent probe ampliﬁcation.
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Russia and Singapore (32%, 40% and 41%, respectively),
Table 3. A variation was noted in deletion rates among studies
carried out even in the same country which could be explained
by the differences in the techniques used, number of exons stud-
ied and different ethnic groups, Tables 2 and 3.
Single exon deletion constituted more than half of the dele-
tion mutations (56%). This is consistent with a previous Egyp-
tian study of Shawky et al., while Effat et al. reported on single
exon deletions in only 40% of Egyptian patients [8,10].
Exon 45 was the most frequent single deleted exon in our
patients, which has also been reported by others [8,10,33]. On
the other hand, exon 50 was the most common single deleted
exon in Indian and Pakistani populations [34,35] while exon
44 was found more often deleted in a Turkish population [33].
Noteworthy was that patient No. 2 presented with severe
symptoms in spite of maintaining the reading frame which
could be explained by exon skipping or deletion at the exon–
intron boundaries affecting splicing behavior [36]. Also, intra-
genic deletions involving the 50 end of the dystrophin gene
(deletion of muscle protomor and exon 1) in patient No. 11
was found to be associated with earlier disease onset (2 years)
and more severe symptoms (wheel-chaired at age of 9 years)
but without any cardiac involvement at the time of study.
The same ﬁnding was previously reported [37]. This rare type
of deletion has been linked in earlier reports with severe dilated
cardiomyopathy with or without skeletal muscle weakness[38–40]. It is known that the effect of deletion of exon 1 is
not predictable on the basis of the effect of the deletion on
the reading frame [41].
A nonsense point mutation was observed in two brothers
from one family (c.583C>T) creating a stop codon in exon
7 (p.Arg195X). To the best of our knowledge, this is the ﬁrst
report of point mutation in Egyptian DMD patients, although
it was reported in different ethnic groups [42]. These two
brothers were similar regarding muscle weakness but com-
pletely different in their cognitive abilities (while the older
child is the top in his class, the younger was mentally retarded).
Previous studies reported a correlation for IQ values in
affected siblings with the same deletion mutation, but a poor
correlation between unrelated affected individuals carrying
the same mutation [43–45].
Out of the 18 families, 3 (16.6%) did not show any patho-
genic mutations by using the methods as outlined. This per-
centage is higher than that previously reported who used the
same testing approach but had only 4% cases with no detect-
able mutation [17]. This could be explained that these cases
represent another type of muscular dystrophy rather than
DMD and can be conﬁrmed only by immunohistochemistry
of muscle biopsy which is considered as a gold-standard for
DMD diagnosis despite its invasiveness. Another explanation
is that we missed the variants such as deep intronic changes,
which Del Gaudio et al. reported approximately 2% of
DMD cases [46].
Table 3 Comparison of frequency of dystrophin gene deletions in different countries.
Country Authors Methods No. of exons tested % of deletion
Kuwait Haider et al., [22] mPCR 25 86
Saudi Arabia Al-Jumah et al., [23] mPCR 25 78
Canada Stockley et al., [24] qPCR All 79 73
China Wang et al., [25] MLPA All 79 66
Greece Florentin et al., [26] mPCR 18 63
Morocco El Sbiti et al., [27] mPCR 18 59
Turkey Battalogue et al., [28] mPCR 18 59
China Lu et al., [29] MLPA All 79 49
Russia Baranov et al., [30] mPCR 10 41
Saudi Arabia Tayeb, [31] mPCR 9 40
Singapore Lai et al., [32] mPCR 19 40
Vietnam Lai et al., [32] mPCR 19 32
Present study (Egypt) PCR, MLPA All 79 50
mPCR: multiples PCR, qPCR: quantitative PCR, MLPA: multiplex ligation-dependent probe ampliﬁcation.
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Our study revealed higher frequencies of duplication muta-
tions (27.8%) in Egyptian patients with DMD than previously
reported which indicates that MLPA should be included in the
genetic screening of affected Egyptian patients. Furthermore,
we conﬁrm in this analysis that there is some variability in
the phenotype even in carriers of the same genotype. Since
newly introduced molecular therapies may revolutionize out-
come in patients, genetic diagnostics is essential to achieve to
identify the molecular defect in each patient if possible. MLPA
serves as an excellent tool to improve the rate of molecular
diagnosis in DMD patients also in Egypt.Declaration of conﬂicting interests
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